INVESTIGATING SAFETY AND EFFICACY OF TTFIELDS PRIOR AND CONCOMITANT TO RADIOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA - FIRST RESULTS OF THE PRICOTTF PHASE I/II TRIAL

被引：0

作者：

Kebir, Sied ^{[1
,2
]}

Lazaridis, Lazaros ^{[1
,2
]}

Schmidt, Teresa ^{[1
,2
]}

Oster, Christoph ^{[1
,2
]}

Feldheim, Jonas ^{[3
,4
]}

Pierscianek, Daniela ^{[5
]}

Proescholdt, Martin ^{[6
]}

Hau, Peter ^{[7
,8
]}

Grosu, Anca-Ligia ^{[9
]}

Krex, Dietmar ^{[10
]}

Sure, Ulrich ^{[11
]}

Scheffler, Bjoern ^{[12
]}

Kleinschnitz, Christoph ^{[1
,2
]}

Poettgen, Christoph ^{[13
]}

Stuschke, Martin ^{[14
]}

Glas, Martin ^{[1
,2
]}

机构：

[1] Univ Duisburg Essen, Univ Med Essen, Dept Neurol, Essen, Germany

[2] Univ Duisburg Essen, Univ Med Essen, Div Clin Neurooncol, Ctr Translat Neuro & Behav Sci C TNBS, Essen, Germany

[3] Univ Med Essen, Dept Neurol, Essen, Germany

[4] Univ Med Essen, Div Clin Neurooncol, Ctr Translat Neuro & Behav Sci C TNBS, Essen, Germany

[5] Univ Med Essen, Dept Neurosurg & Spine Surg, Essen, Germany

[6] Univ Regensburg, Dept Neurosurg, Med Ctr, Regensburg, Germany

[7] Univ Hosp Regensburg, Dept Neurol, Regensburg, CA USA

[8] Univ Hosp Regensburg, Wilhelm Sander Neurooncol Unit, Regensburg, CA USA

[9] Med Ctr Univ Freiburg, Dept Radiat Oncol, Freiburg, Germany

[10] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Neurosurg, Dresden, Germany

[11] Univ Duisburg Essen, Univ Med Essen, Dept Neurosurg & Spine Surg, Essen, Germany

[12] German Canc Res Ctr, Heidelberg, Germany

[13] Univ Med Essen, Dept Radiotherapy, Essen, Germany

[14] Univ Duisburg Essen, Univ Med Essen, Dept Radiotherapy, Essen, Germany

来源：

NEURO-ONCOLOGY | 2023年 / 25卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CTNI-65

引用

页数：2

共 50 条

[31] Phase 1 trial of ralimetinib (LY2228820) with radiotherapy plus concomitant temozolomide in the treatment of newly diagnosed glioblastoma
Biau, J.
Thivat, E.
Chautard, E.
Stefan, D.
Boone, M.
Chauffert, B.
Bourgne, C.
Richard, D.
Molnar, I
Levesque, S.
Bellini, R.
Kwiatkowski, F.
Karayan-Tapon, L.
Verrelle, P.
Godfraind, C.
Durando, X.
RADIOTHERAPY AND ONCOLOGY, 2021, 154 : 227 - 234
[32] The Efficacy and Safety of RAD (Lenalidomide, Adriamycin and Dexamethasone) In Newly Diagnosed Multiple Myeloma - First Results of a phase II Trial by the German DSMM Group
Knop, Stefan
Langer, Christian
Engelhardt, Monika
Muegge, Lars
Reichle, Albrecht
Roellig, Christoph
Gramatzki, Martin
Roesler, Wolf
Topp, Max S.
Wesemeier, Carmen
Hertenstein, Bernd
Sturm, Isrid
Dechow, Tobias
Kortuem, Martin
Sauerwein, Marianne
Einsele, Hermann
Bargou, Ralf
BLOOD, 2010, 116 (21) : 810 - 810
[33] Tumor treating fields and radiotherapy for newly diagnosed glioblastoma: safety and efficacy-results from a pilot study
Grossman, R.
Bokstein, F.
Blumenthal, D.
Ben Harush, C.
Limon, D.
Ram, Z.
STRAHLENTHERAPIE UND ONKOLOGIE, 2019, 195 : S64 - S64
[34] CONCOMITANT RADIO CHEMOTHERAPY WITH CCNU IN NEWLY DIAGNOSED GLIOBLASTOMA: PRELIMINARY RESULTS OF A SINGLE INSTITUTION PHASE II STUDY
Kaloshi, G.
Spahiu, O.
Djamandi, P.
Djamandi, P.
Ruka, M.
Haxhihyseni, E.
Bushati, T.
Petrela, M.
NEURO-ONCOLOGY, 2012, 14 : 56 - 56
[35] Concomitant radio chemotherapy with CCNU in newly diagnosed glioblastoma: preliminary results of a single institution phase II study
Brace, G.
Ranxha, E.
Cakciri, G.
Rroji, A.
Fejzo, G.
Spahiu, O.
Petrela, M.
Kaloshi, G.
EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 : 763 - 763
[36] PHASE II TRIAL OF A SURVIVIN VACCINE (SurVaxM) FOR NEWLY DIAGNOSED GLIOBLASTOMA
Ahluwalia, Manmeet
Reardon, David
Abad, Ajay
Curry, William
Wong, Eric
Peereboom, David
Belal, Ahmed
Qiu, Jingxin
Mogensen, Kathleen
Schilero, Cathy
Casucci, Danielle
Mechtler, Laszlo
Uhlmann, Erik
Ciesielski, Michael
Fenstermaker, Robert
NEURO-ONCOLOGY, 2018, 20 : 10 - 11
[37] PHASE II TRIAL OF SURVAXM PLUS TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA
Ahluwalia, Manmeet
Ciesielski, Michael J.
Reardon, David A.
Abad, Ajay
Curry, William
Wong, Eric
Peereboom, David
Figel, Sheila
Hutson, Alan
Groman, Adrienne
Withers, Henry
Liu, Song
Belal, Ahmed
Qiu, Jingxin
Mogensen, Kathleen
Schilero, Cathy
Khosla, Atulya
Casucci, Danielle
Mechtler, Laszlo
Fenstermaker, Robert
NEURO-ONCOLOGY, 2022, 24 : 66 - 66
[38] Temozolomide and concurrent radiotherapy in patients with glioblastoma multiforme -: First results of a phase II trial
Micke, O
Schäfer, U
Schüller, P
Schul, C
Willich, N
STRAHLENTHERAPIE UND ONKOLOGIE, 2004, 180 : 36 - 36
[39] Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study
Nagane, Motoo
Ichimura, Koichi
Onuki, Ritsuko
Narushima, Daichi
Honda-Kitahara, Mai
Satomi, Kaishi
Tomiyama, Arata
Arai, Yasuhito
Shibata, Tatsuhiro
Narita, Yoshitaka
Uzuka, Takeo
Nakamura, Hideo
Nakada, Mitsutoshi
Arakawa, Yoshiki
Ohnishi, Takanori
Mukasa, Akitake
Tanaka, Shota
Wakabayashi, Toshihiko
Aoki, Tomokazu
Aoki, Shigeki
Shibui, Soichiro
Matsutani, Masao
Ishizawa, Keisuke
Yokoo, Hideaki
Suzuki, Hiroyoshi
Morita, Satoshi
Kato, Mamoru
Nishikawa, Ryo
CANCERS, 2022, 14 (22)
[40] SAFETY AND EFFICACY OF TEMOZOLOMIDE TREATMENT WITH NEWLY DIAGNOSED GLIOBLASTOMA IN JAPAN: A MULTICENTER PHASE II CLINICAL STUDY
Sugiyama, Kazuhiko
Nishikawa, Ryo
Takeshima, Hideo
Nakamura, Hideo
Aoki, Tomokazu
Takahashi, Jun
Takahash, Hideaki
Saito, Akihiko
Sawamura, Yutaka
Kurisu, Kaoru
Matsutani, Masao
NEURO-ONCOLOGY, 2009, 11 (06) : 948 - 948

← 1 2 3 4 5 →